The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Files Add’l Indication of MS for Solu-Medrol Based on Data from Public Domain
September 13, 2012
- Eli Lilly Files Public Knowledge-Based Application for Gemzar for Malignant Lymphoma
September 12, 2012
- Wholesalers Unlikely to See Significant Progress in Price Negotiations By End of September
September 12, 2012
- Taisho Toyama, Eisai Launch Anti-Rheumatic Drug Kolbet/Careram on Sept. 12
September 12, 2012
- 6.3% Increase in Ethical Drug Sales in July: Crecon Report
September 11, 2012
- “Legal Compliance” Part of Employee Evaluations in Sales Division, Including Possible Cuts in Bonuses for Managers: MSD
September 11, 2012
- Pharmaceutical Companies Beefing Up Training for Cancer Specialized MRs
September 11, 2012
- US Pfizer Obtains EU Marketing Authorization for Inlyta
September 11, 2012
- DSP Files Additional Indications for Bipolar I Disorder for Latuda in US
September 11, 2012
- Sanofi Pasteur Says It Cannot Meet MHWL Request to Lower IPV Price
September 11, 2012
- Eisai Receives Australian Approval for Halaven
September 10, 2012
- DSP Revising Midterm Business Plan – Will It Be Able to Hammer Out Effective Measures against Stagnant Domestic Business?
September 10, 2012
- Fuji-Keizai Predicts Antidepressant Market to Exceed 170 Billion Yen in 2020
September 7, 2012
- Kissei Aims for 40% Market Share for Epoetin Alfa at Early Stage
September 7, 2012
- Kyorin to Appoint Yoshida of MSD as Kyorin Pharmaceutical Facilities President
September 7, 2012
- Sunovion Completes Acquisition of Elevation: DSP
September 7, 2012
- Revestive Receives European Market Authorization for Short Bowel Syndrome: Takeda
September 6, 2012
- Nippon Shinyaku Plans Generic Launch to Complement Its New Drug Lineup in Priority Field
September 6, 2012
- AZ Aims to Become Market Leader with Symbicort on Additional Indication for COPD
September 6, 2012
- DSP Submits Imported Drug Registration Application in China for Anticancer Agent Calsed
September 6, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…